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ABSTRACT (Word count: 250; maximum: 250) 
 
Effector memory T-cell (TEM) responses display potent antiviral properties and 
have been linked to stringent control of simian immunodeficiency virus (SIV) replication. 
Since recurrent antigen stimulation drives the differentiation of CD8+ T-cells toward the 
TEM phenotype, here we incorporated a persistent herpesviral vector into a heterologous 
prime/boost/boost vaccine approach in order to maximize the induction of TEM 
responses. This new regimen resulted in CD8+ TEM-biased responses in four rhesus 
macaques, three of which controlled viral replication to <1,000 viral RNA copies/mL of 
plasma for more than six months after infection with SIVmac239. Over the course of this 
study, we made a series of interesting observations in one of these successful controller 
animals. Indeed, in vivo elimination of CD8αβ+ T-cells using a new CD8β-depleting 
antibody did not abrogate virologic control in this monkey. Only after its CD8α+ 
lymphocytes were depleted did SIV rebound, suggesting that CD8αα+ but not CD8αβ+ 
cells were controlling viral replication. By two weeks post infection, the only SIV 
sequences that could be detected in this animal harbored a small in-frame deletion in 
nef affecting six amino acids. Deep sequencing of the SIVmac239 challenge stock 
revealed no evidence of this polymorphism. However, sequencing of the rebound virus 
following CD8α depletion at week 38.4 post infection again revealed only the six-amino 
acid deletion in nef. While any role for immunological pressure on the selection of this 
deleted variant remains uncertain, our data provide anecdotal evidence that control of 
SIV replication can be maintained without an intact CD8αβ+ T-cell compartment.  
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INTRODUCTION 
 
The rationale for engendering HIV-specific CD8+ T-cell responses by vaccination 
comes from a wealth of data indicating that cellular immunity can limit viral replication in 
vivo.1–5 While eliciting efficacious CD8+ T-cells against this virus has not been 
straightforward, as evidenced by the failures in clinical trials of all HIV-1 vaccine 
regimens aimed at inducing CD8+ T-cell responses tested to date,6–8 valuable insights 
have been gained from the SIV/rhesus macaque model. For example, live-attenuated 
SIV vaccines have consistently afforded the greatest levels of efficacy against challenge 
with the pathogenic SIVmac239 clone.9, 10 Although protection in these cases is likely 
multifactorial, Fukazawa et al. have recently shown that the magnitude of effector-
differentiated T-cell responses in lymph nodes of vaccinated macaques correlates with 
the efficacy of live-attenuated SIV vaccines.10 Importantly, the maintenance of these 
protective SIV-specific T-cells correlated with the ability of live-attenuated SIV vaccines 
to persistently replicate at low levels in lymph nodes. By comparison, the majority of 
HIV/SIV vaccine platforms tested to date consist of weakened or replication-defective 
vectors that provide only transient antigen (Ag) exposure.11–14 Although T-cell 
responses elicited by these conventional vector platforms have often exhibited 
satisfactory immunogenicity profiles, their performance in stringent SIV challenge trials 
has varied considerably, ranging from no protection to partial virologic control.15–19 
Given the superior outcomes achieved with live-attenuated SIV vaccines, regimens that 
safely provide recurrent low-level exposure to viral proteins might facilitate the induction 
of effective anti-lentiviral T-cell immunity. 
Herpesviruses establish latent infections that persist for the life of the host.20 
Similar to live-attenuated SIV vaccination, herpes viral infections result in persistent Ag 
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stimulation, which favors the induction of effector memory T-cell (TEM) responses.21 This 
phenotype is associated with T-cells that recirculate through extralymphoid tissues and 
are poised for immediate antiviral activity.22 The persistent nature of herpesviruses and 
the antiviral properties of TEM prompted the generation of live recombinant (r) 
herpesviral vectors encoding SIV proteins. For example, a fibroblast-adapted strain of 
the β-herpesvirus rhesus cytomegalovirus (RhCMV) expressing SIV inserts has shown 
great promise in monkey trials with approximately half of RhCMV/SIV vaccinees 
manifesting early and profound control of viral replication after SIVmac239 infection.23, 24 
Remarkably, these protected vaccinees eventually cleared SIV in vivo, implying that 
lentiviral infections are vulnerable to early interception by vaccine-induced TEM 
responses.25 Importantly, RhCMV is not the only herpesviral vector platform available 
for persistent antigen delivery in nonhuman primates. In fact, a genetic system for the 
γ2-herpesvirus rhesus monkey rhadinovirus (RRV) has also been developed,26 
facilitating the generation of rRRV/SIV vectors.27 In contrast to the unconventionally 
major histocompatibility complex (MHC)-restricted CD8+ TEM responses elicited by the 
aforementioned RhCMV strain,28, 29 rRRV/SIV-vaccinated macaques develop CD8+ T-
cells capable of recognizing classically immunodominant MHC class I-restricted SIV 
epitopes.27 Following intravenous challenge with SIVmac239, rRRV/SIV vaccinees 
manifested significant reductions in peak and setpoint viremia compared to 
unvaccinated controls. Collectively, these data highlight the utility of herpesviral vectors 
for eliciting lentivirus-specific TEM responses.  
Repeated Ag stimulation delivered in the form of heterologous prime/boost/boost 
(PBB) immunization protocols has been shown to generate robust CD8+ TEM responses 
in mice.30, 31 Similarly, we have recently shown that a rDNA prime followed by boosting 
with rYF17D and rAd5 resulted in high frequency SIV-specific TEM responses in rhesus 
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macaques.32 However, these vaccine-induced CD8+ T-cells underwent considerable 
contraction soon after the rAd5 boost, possibly due to the lack of persistent Ag 
stimulation afforded by the rDNA/rYF17D/rAd5 protocol. In an attempt to improve the 
maintenance of CD8+ TEM responses, we delivered a final rRRV/SIV boost to four 
rhesus macaques that had been immunized with a rDNA prime followed by a rYF17D 
boost. In addition to evaluating the immunogenicity and efficacy of this new 
rDNA/rYF17D/rRRV regimen, this pilot study resulted in an extraordinary outcome in 
one of the vaccinated monkeys. Using viral sequencing and selective depletions of 
CD8β- or CD8α-expressing lymphocytes in vivo, we investigated immunological and 
virologic aspects of this rare case of control of SIVmac239 replication.  
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MATERIALS AND METHODS 
 
Research Animals 
The four Indian rhesus macaques used in the vaccine pilot study described in 
Figure 1 were naturally infected with RRV. The two SIV-infected Indian rhesus 
macaques used in the experiment described in Figure 4 were part of a recent study 
conducted by our laboratory and were used to further characterize the effects of CD8β 
depletion during controlled SIV infection. All animals were housed at the Wisconsin 
National Primate Research Center (WNPRC) and cared for in accordance with the 
Weatherall Report under a protocol approved by the University of Wisconsin Graduate 
School Animal Care and Use Committee. Vaccinations, SIV challenges, and 
monoclonal antibody (mAb) infusions were performed under anesthesia and all efforts 
were made to minimize potential suffering. Additional animal information, including MHC 
class I alleles, age, and sex, is shown in Table 1. 
 
Vaccinations 
The macaques in Groups 1 and 2 were primed once with rDNA plasmids 
expressing SIVmac239 minigenes encoding Nef amino acids (aa) 45-210 (Group 1) or 
Gag aa 178-258 (Group 2). One milligram of each rDNA/SIV vector and 0.1 mg of an IL-
12-expressing plasmid were co-delivered by intramuscular electroporation. The 
monkeys then received 300,000 plaque-forming units of rYF17D vectors encoding the 
same inserts as the rDNA plasmids via the subcutaneous route. Additional information 
on the rDNA and rYF17D vaccinations can be found elsewhere.33 The third and last 
vaccine boost consisted of a single infusion of 1.0 mL of phosphate-buffered saline 
(PBS) solution containing 7.0×108 genome copies of rRRV vectors encoding 
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SIVmac239 inserts. Animals in Group 1 received rRRV/rev-tat-nef while those in Group 
2 were vaccinated with rRRV/gag (Fig. 1A). The construction of these rRRV/SIV 
vaccines has been described elsewhere.27  
 
SIVmac239 challenges 
   
The challenge stock utilized here was produced by the Virology Services Unit of 
the WNPRC using SIVmac239 hemi-genome plasmids obtained from the NIH AIDS 
Research and Reference Reagent Program. These plasmids were transfected into 293T 
cells and the supernatant was propagated on mitogen-activated PBMC from SIV naïve 
rhesus macaques for several days. The titer of this stock was 90,000 50% tissue culture 
infective doses (TCID50)/mL. Animals in this study were subjected to the same weekly 
intrarectal (IR) SIVmac239 challenge regimen described recently.32 The dose of each 
exposure was 200 TCID50, which corresponded to 4.8×105 viral RNA (vRNA) copies. 
Plasma viral loads (VLs) were assessed three and seven days after each exposure. 
Once an animal had a positive VL, it was no longer challenged.  
 
In vivo CD8 depletions 
 CD8β-expressing lymphocytes were transiently depleted using the anti-CD8β 
mAb CD8β255R1. The parental mouse mAb was raised against rhesus CD8β chain and 
engineered into a recombinant rhesus IgG1 by complementarity-determining region 
(CDR) grafting. CD8α+ cells were depleted using a CDR-grafted rhesus IgG1, 
MT807R1, derived from a mouse anti-human CD8α mAb.34 All animals were 
administered a single intravenous injection of 50 mg/kg of body weight. Both mAbs were 
provided by the NIH Nonhuman Primate Reagent Resource (Boston, MA).  
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MHC class I tetramer staining and immunophenotyping during lymphocyte depletions 
 We monitored the ontogeny of vaccine-induced SIV-specific CD8+ T-cell 
responses in Groups 1 and 2 using fluorochrome-labeled MHC class I tetramers, as 
described recently.35 In sum, peripheral blood mononuclear cells (PBMC) were isolated 
from blood drawn at the WNPRC on the previous day and then shipped to the University 
of Miami overnight. We used allophycocyanin-conjugated Mamu-B*08/Nef137-146RL10 
(NIH Tetramer Core Facility) and Mamu-A*01/Gag181-189CM9 (MBL International) 
tetramers to monitor vaccine-induced SIV-specific CD8+ T-cell responses in the Group 1 
and Group 2 macaques, respectively. Up to 800,000 PBMC were incubated with titrated 
amounts of each tetramer at 37°C for one hour and then stained with fluorochrome-
labeled antibodies directed against the surface molecules CD3 (clone SP34-2), CD8α 
(clone RPA-T8), CD28 (clone 28.2), CCR7 (clone 150503), CD14 (clone M5E2), CD16 
(clone 3G8), and CD20 (clone 2H7). Amine-reactive dye (ARD; Live/DEAD Fixable 
Aqua Dead Cell Stain; Life Technologies) was also added to this mAb cocktail. After a 
25-min incubation at room temperature (RT), the cells were washed with Wash Buffer 
(Dulbecco’s PBS with 0.1% bovine serum albumin and 0.45 g/L NaN3) and then fixed 
with PBS containing 2% of paraformaldehyde. The configuration of the Special Order 
Product BD LSR II cytometer used to acquire the samples and the gating strategy 
employed to analyze the data have been detailed elsewhere.32 In sum, we used FlowJo 
9.6 to determine the percentages of live CD14–CD16–CD20– CD3+CD8+tetramer+ 
lymphocytes displayed on Figure 1B & C and to delineate memory subsets within 
tetramer+ populations (Fig. 1D & E).  
 To monitor the frequencies of lymphocyte subsets during the CD8β and CD8α 
depletions, our surface staining master mix included the same clones of anti-CD3, anti-
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CD14, anti-CD16, and anti-CD20 antibodies and the same ARD reagent mentioned 
above. Additionally, this cocktail included antibodies against the CD8α chain (clone SK1 
for the CD8β depletion phase or clone DK25 for the CD8α depletion phase) and the 
CD8αβ heterodimer (clone 2ST8-5H7). This latter clone recognizes a conformational 
epitope consisting of domains from both the CD8α and CD8β chains.36 Of note, the CD8 
glycoprotein can be expressed as two isoforms: CD8αβ heterodimers or CD8αα 
homodimers.37 The anti-CD8α mAb MT807R1 that was used to deplete CD8α+ 
lymphocytes in vivo is known to cross-block other anti-CD8 antibodies used for 
immunophenotyping. Ho ever, the anti-CD8α clone DK25 can still resolve CD8α+ cells 
in the presence of MT807R1, albeit with reduced fluorescence intensity.34 In quality 
assessment tests performed in our laboratory, we found that pre-incubation of PBMC 
with 50 µg/mL of the anti-CD8β mAb CD8β255R1 did not prevent fluorochrome-labeled 
2ST8-5H7 antibodies from detecting CD8αβ+ T-cells, although there was a slight 
reduction in fluorescence intensity (data not shown). In contrast, pre-incubation of 
PBMC with 50 µg/mL of MT807R1 completely blocked staining with 2ST8-5H7. During 
the CD8β depletion phase, CD3+ T-lymphocytes that were positive for CD8α but 
negative for CD8αβ were considered to be CD8αα+. To obtain relative frequencies of 
lymphocyte subsets, we first excluded monocytes, B-cells, and dead cells in the “dump 
gate” (CD14+CD20+ARD+) and then determined the percentages of CD8αβ+ T-cells 
(CD3+CD8αα–CD8αβ+), CD8αα+ T-cells (CD3+CD8αα+CD8αβ–), CD4+ T-cells 
(considered as CD3+CD8αα–CD8αβ–), and NK cells (CD3–CD8αα+CD16+) within the 
lymphocyte gate. Absolute counts of these subsets were then calculated by multiplying 
their respective frequencies by the absolute number of white blood cells obtained from 
matching complete blood counts.   
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Intracellular cytokine staining (ICS) assay 
 The ICS assay was performed as described recently.32 In sum, cells were 
stimulated with SIV peptides at a final concentration of 1.0 µM in the presence of co-
stimulatory mAbs against CD28 (clone L293; BD Biosciences) and CD49d (clone 9F10; 
BD Pharmingen) for 9 h at 37 °C in a 5.0% CO2 incubator. To inhibit protein transport, 
Brefeldin A (Biolegend, Inc.) and GolgiStop (BD Biosciences) were added to all tubes 1 
h into the incubation period. We employed the same steps outlined above to stain 
molecules on the surface of cells and to fix them with 2% of paraformaldehyde. In 
addition to the same mAbs against CD14, CD16, and CD20 and the ARD reagent 
described above, the surface staining master mix also included mAbs against CD4 
(clone OKT4; Biolegend, Inc.) and CD8 (clone RPA-T8; Biolegend, Inc.). Cells were 
permeabilized by resuspending them in “Perm Buffer” (1× BD FACS lysing solution 2 
[Beckton Dickinson] and 0.05% Tween 20 [Sigma-Aldrich]) for 10 min and subsequently 
washed with Wash Buffer. Cells were then incubated with mAbs against IFN-γ (clone 
4S.B3; Biolegend, Inc.), TNF-α (clone Mab11; BD Biosciences), and CD3 (same one 
mentioned above) for 1 h in the dark at RT, washed, and subsequently stored at 4 °C 
until acquisition.  
 
Anti-immunoglobulin (Ig) ELISA 
 ELISA plates (Nunc-Immuno) were coated overnight at 4°C with either MT807R1 
or CD8β255R1. All subsequent steps and incubations were performed at RT. On the 
following day, plates were washed five times with Wash Buffer (PBS containing 0.05% 
of Tween 20) and then blocked with SuperBlock buffer (Thermo Scientific) for 15 min. 
Plasma from r04132 and r08019 collected 8 days prior to (pre-depletion) or 22 days 
after (post-depletion) the anti-CD8β mAb infusion was used in this assay. Plasma from 
Page 13 of 60
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
AIDS Research and Human Retroviruses
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only; Not for Distribution 11
untreated or anti-CD8α-treated monkeys was used as negative and positive controls, 
respectively. After diluting plasma samples 10-fold in PBS containing 2% of bovine 
serum albumin, these aliquots were serially diluted 1:4 until a dilution factor of 10,240 
was achieved. One hundred µL of these serially diluted plasma aliquots were added to 
plates, followed by a 1-h incubation. Subsequently, plates were washed 5 times and 
100 µL of a 100-fold dilution of anti-Ig human λ light chain-conjugated to biotin (Miltenyi 
Biotec) were added to each well and incubated for one hour. Plates were then washed 
five times before 100 µL of a 10,000-fold dilution of horseradish peroxidase-conjugated 
Streptavidin (Invitrogen) ere added to each well. After a 1-h incubation, plates were 
washed five times. One hundred µL of TMB (Calbiochem) were added to the plates for 
approximately 3 min and then the substrate reaction was stopped with H2SO4 Stop 
Solution (Southern Biotech). The optical density (OD) of each well was determined on 
an ELISA reader using a 450-nm filter. Endpoint titers of anti-Ig antibodies were 
considered as the highest dilutions where the OD of the post-depletion sample was >2-
fold higher than its pre-depletion counterpart.  
 
SIV viral load measurements 
 VLs were measured using 0.5 mL of EDTA-anticoagulated plasma based on a 
modification of a previously published protocol.38 Total RNA was extracted from plasma 
samples using QIAgen DSP virus/pathogen Midi kits, on a QIASymphonyXP laboratory 
automation instrument platform. Six replicate two step RT-PCR reactions were 
performed per sample using a random primed reverse transcription reaction, followed 
by 45 cycles of PCR using the following primers and probe: forward primer:  SGAG21: 
5’-GTCTGCGTCAT(dP)TGGTGCATTC-3’; reverse primer SGAG22: 5’-
CACTAG(dK)TGTCTCTGCACTAT(dP)TGTTTTG-3’; probe: PSGAG23: 5’-FAM-
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CTTC(dP)TCAGT(dK)TGTTTCACTTTCTCTTCTGCG-BHQ1-3’. The limit of reliable 
quantitation on an input volume of 0.5 mL of plasma was 15 vRNA copies/mL. 
 
Whole-genome deep sequencing of SIVmac239 
Viral RNA in plasma was isolated using the QIAamp viral RNA mini kit (Qiagen), 
according to the manufacturer’s protocol, and eluted in 60 µl of AVE buffer. The eluate 
was then aliquoted and stored at −80°C for future use. Viral RNA was reverse 
transcribed and amplified by using the SuperScript III One-Step RT-PCR system with 
High Fidelity Platinum Taq polymerase (Invitrogen). PBMCs from rhesus macaque were 
washed twice with PBS and DNA was then extracted from the cells using the QiAMP 
DNA Blood Mini Kit (Qiagen) with PCR amplifications performed as described below 
with the exception of the first RT step. For the r08019 wk 38.4 PI sample, a near full-
length genome of SIV was amplified in four segments using the following primers: 
Amp1-F (5′-AGGAACCAACCACGACGGAG-3′) and Amp1-R (5′-
AAAGGGATTGGCACTGGTGCGAGG-3′); Amp2-F (5′-
TGCTGACGGCTTGTCAAGGAGTAGG-3′) and Amp2-R (5′-
ACCCTGTCATGTTCCAGGTCTGTCC-3′); Amp3-F (5′-
ATGGTGGGCAGGGATAGAGC-3′) and Amp3-R (5′-CCATGCCTGCTTTGGCCTAT-3′); 
Amp4-F (5′-TGCACAGGCTTGGAACAAGA-3′) and Amp4-R (5′-
ACATCCCCTTGTGGAAAGTC-3′). The RT-PCR conditions were as follows for Amp 1 
and 2: 50 °C for 30 min; 94 °C for 2 min; 40 cycles of 94 °C for 15 sec, 55 °C for 30 sec, 
and 68 °C for 3 min; and 68 °C for 5 min and for Amp 3 and 4: 45 °C for 120 min, 94 °C 
for 15 sec; 40 cycles of 94 °C for 15 sec, 50 °C for 30 sec, and 68 °C for 6 min; and 68 
°C for 6 min. In the case of PBMC from r08019 collected at wk 2 PI, only one amplicon 
was successfully amplified and sequenced, despite multiple attempts using different 
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primer sets and conditions. A 2.4-kb fragment spanning part of env and nef (positions 
7,565-9,979) amplified using forward primer (5′-CAGTCACCATTATGTCTGGATTG-3′) 
and reverse primer (5′-GAATACAGAGCGAAATGCAGTG-3′) under the conditions 
detailed above for amp 1 and 2. A smaller amplicon-based 454 sequencing approach 
was used to analyze a 400-bp region in Nef as previously described.39 Whole genome 
deep sequencing was also performed on the SIVmac239 challenge as previously 
described.40 
Amplicons were visualized on a 1.0% agarose gel and purified using the Purelink 
quick gel extraction kit (Invitrogen). RT-PCR products were quantified using a Promega 
quantiflor-ST fluorometer (Promega) and analyzed for quality using an Agilent 2100 
bioanalyzer with high sensitivity DNA chips. PCR amplicons were fragmented and 
barcoded using NexteraXT DNA Library Prep Kit, as per manufacturer’s protocol.  
Samples were pooled and sequenced on an Illumina MiSeq platform, using a 2 x 250-
bp V2 reagent kit. Paired-end reads obtained from Illumina MiSeq were assembled into 
a SIV consensus sequence using the VICUNA de novo assembler software and finished 
with V-FAT v1.0.41 Reads were mapped back to this consensus using Mosaik v2.1.73, 
and intra-host variants called by V-Phaser v2.0.42, 43 All reads have been deposited to 
the NCBI Sequence Read Archive under accession number SRP016012.  
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RESULTS 
 
Four rhesus macaques were equally divided between two groups based on their 
MHC class I alleles: monkeys in Group 1 were Mamu-B*08+ and those in Group 2 were 
Mamu-A*01+ (Fig. 1A). We chose these MHC class I alleles because their gene 
products present immunodominant SIV epitopes. Specifically, Mamu-B*08 binds to 
Nef137-146RL10 while Mamu-A*01 restricts Gag181-189CM9.44, 45 Of note, expression of 
Mamu-B*08 has been linked to elite control of SIVmac239 infection.46 
To achieve the continual Ag stimulation that favors induction of TEM responses,21, 
47 we combined the repetitive boosting provided by heterologous PBB regimens and the 
persistent Ag exposure afforded by herpesviral infections into a new immunization 
protocol. This protocol consisted of successive vaccinations with electroporated rDNA, 
rYF17D, and rRRV vectors encoding SIVmac239 inserts (Fig. 1A). The vectors 
employed in Group 1 and Group 2 delivered the Nef137-146RL10 and Gag181-189CM9 
epitopes, respectively, to match the expressed MHC class I alleles (Fig. 1A). To monitor 
the ontogeny of vaccine-induced CD8+ T-cell responses against each epitope, we 
performed longitudinal fluorochrome-labeled MHC class I tetramer stainings in PBMC 
from the Group 1 and Group 2 animals. The two Mamu-B*08+ vaccinees developed low 
frequency responses against Nef137-146RL10, with percentages of tetramer+CD8+ T-cells 
peaking at 4% and then decreasing to <1% of CD8+ T-cells by wk 34 post rYF17D (Fig. 
1B). Conversely, both Mamu-A*01+ animals in Group 2 mounted robust Gag181-189CM9-
specific CD8+ T-cells after the rRRV boost (14% and 16% at peak; Fig. 1C). While the 
magnitude of these tetramer+CD8+ T-cells eventually declined to <1% in r01049, the 
other Group 2 vaccinee (r08019) maintained its Gag181-189CM9-specific response at 
4.6% after resolution of the peak response (Fig. 1C). It is not entirely clear why the 
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contraction of vaccine-induced SIV-specific CD8+ T-cells was accentuated in both 
Group 1 animals and in r01049 in the weeks following the rRRV boost. Given that 
captive rhesus monkeys can be naturally infected with RRV,48, 49 pre-existing immunity 
to this herpesvirus may have limited the “take” of the live rRRV vectors utilized here. 
Indeed, all four monkeys in Groups 1 and 2 were seropositive for RRV at the time of the 
rRRV vaccination (data not shown).  
We also carried out a phenotypic analysis of vaccine-induced SIV-specific CD8+ 
T-cells at wk 34 post rYF17D and found a predominance of the fully differentiated TEM2 
(CD28−CCR7−) phenotype (Fig. 1D & E), indicative of persistent Ag stimulation. 
Transitional memory  (TEM1; CD28+CCR7−) and central memory (TCM; CD28+CCR7+) 
tetramer+CD8+ T-cells were also detected, especially in the Group 1 vaccinee r04132 
(Fig. 1D). In sum, while 3/4 vaccinees had low frequencies of SIV-specific CD8+ T-cells 
at the time of SIV challenge, r08019 was clearly an outlier since >4% of its peripheral 
CD8+ T-cell compartment was specific for a single SIV epitope and 96% of these 
exhibited the TEM2 phenotype. 
At wk 19 post rRRV boost, we began challenging all animals intrarectally with 
200 TCID50 of an in vivo-titrated SIVmac239 stock. Of note, out of the 32 SIV naïve 
rhesus macaques that have been subjected to this IR challenge regimen (same viral 
stock and dose) as part of ongoing experiments conducted by our group, 78% became 
infected by the 6th exposure (Martins et al., unpublished observations). Remarkably, 
after becoming infected after the 9th IR challenge (Fig. 1F), the Group 2 vaccinee 
r08019 experienced a peak VL of only 1,000 vRNA copies/mL of plasma and 
subsequently controlled viremia to <15 vRNA copies/mL by wk 5 post infection (PI; Fig. 
1G). In contrast, the other Group 2 animal (r01049) became infected after the 5th 
challenge and failed to suppress viremia (Fig. 1F & G). Encouragingly, both Group 1 
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vaccinees had relatively low peak VLs and controlled chronic phase VLs to <1,000 
vRNA copies/mL (Fig. 1G). As a reference, we compared VLs in Groups 1 and 2 with 
those from MHC class I-matched macaques that were rectally infected with SIVmac239 
as part of previous and ongoing studies conducted by our laboratory (Martins et al., 
unpublished observations).32, 33, 39 These historical controls included both unvaccinated 
and vaccinated monkeys (Fig. 2). Overall, the two Group 1 vaccinees experienced lower 
peak and setpoint VLs than the majority of their Mamu-B*08+ historical counterparts 
while r08019 exhibited the lowest levels of viremia among our cohort of Mamu-A*01+ 
historical controls (Fig. 2). Thus, a rDNA/rYF17D/rRRV regimen encoding 
immunodominant SIV epitopes resulted in stringent control of SIVmac239 replication in 
3/4 vaccinees. 
Given r08019’s remarkable outcome, we then explored several potential 
mechanisms for the impressive virologic control observed in this animal. First, we 
postulated that this animal’s robust vaccine-induced SIV-specific CD8+ T-cell response 
was responsible for containing viral replication. Based on this assumption and on our 
previous experimental data,2 we expected r08019 to transiently lose control of SIV 
replication following infusion of a CD8-depleting mAb. Of interest, the CD8 glycoprotein 
can be expressed as two isoforms: either as a heterodimer consisting of the CD8α and 
CD8β chains (CD8αβ) or as a CD8αα homodimer.37 While CD8αβ marks thymus-
selected MHC class I-restricted T-cells,37, 50 CD8αα is found primarily on mucosal T-
cells and, in the case of rhesus macaques, NK cells as well.51, 52 Historically, in vivo 
depletion of CD8+ lymphocytes in SIV-infected rhesus macaques has been 
accomplished by the infusion of antibodies specific for the CD8α chain.5, 53, 54 An 
important caveat of this approach is the simultaneous elimination of CD8αβ+ T-cells and 
NK cells, which makes it difficult to distinguish the contribution of each lymphocyte 
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subset to control of SIV infection. To avoid this limitation, we used a newly available 
rhesus recombinant CDR-grafted mAb (CD8β255R1) specific for the CD8β chain to 
selectively ablate CD8αβ+ T-cells in r08019 and in both Group 1 macaques (Fig. 3A). 
Importantly, quality assessment tests performed prior to the CD8β depletion confirmed 
that CD8β255R1 did not block the fluorochrome-labeled anti-CD8 antibodies utilized in 
our immunophenotyping assays (see Materials and Methods). A single infusion of 50 
mg/kg of CD8β255R1 readily depleted the majority of peripheral CD8αβ+ T-cells in all 
three animals without eliminating NK cells (Fig. 3B & C). In fact, NK cell numbers 
steadily increased following the CD8β255R1 infusion and peaked at wk 9 post CD8β 
depletion (Fig. 3C). Absolute counts of CD8αα+ T-cells also rose during this period, 
especially in r07032 (Fig. 3D). CD4+ T-lymphocyte counts went up as well (Fig. 3E), 
possibly due to the homeostatic expansion of memory CD4+ T-cells that occurs in 
response to CD8 depletion in vivo.55 Similar to previous CD8α depletion studies in SIV-
infected elite controller macaques,2 elimination of CD8αβ+ T-cells in the Group 1 
animals resulted in a transient increase in viremia (Fig. 3F). While r04132 promptly 
reasserted control of viral replication, VLs in r07032 remained higher than their baseline 
levels for several weeks after the CD8β depletion (Fig. 3F). Interestingly, the rise in 
absolute counts of CD8αα+ T-cells and NK cells coincided with decreases in viremia in 
the Mamu-B*08+ Group 1 macaques (Fig. 3C, D, & F), implying that these CD8αα-
expressing lymphocytes contributed to restoring virologic control in those animals. 
Strikingly, except for borderline VLs (up to 30 vRNA copies/mL) shortly after the CD8β 
depletion, r08019 did not lose control of SIV replication and had undetectable viremia by 
wk 4.4 post CD8β depletion (Fig. 3F). Small increases in SIV-producing cells in lymph 
nodes were also observed in r08019 following depletion of its CD8αβ+ T-lymphocytes, 
as determined by in situ hybridization performed on biopsies collected before and after 
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the mAb infusion (data not shown). This strange result suggested that an intact CD8αβ+ 
T-cell compartment was not necessary for suppressing SIVmac239 replication in 
r08019.  
To determine if the ability of r08019 to maintain control of viral replication in the 
context of CD8αβ+ T-cell deficiency could be manifested by other macaques with 
controlled SIV viremia, we subjected two additional animals to the same CD8β depletion 
regimen described above (Fig. 4). Macaques r09089 and r09037 (Group 3) expressed 
Mamu-B*08+ and both controlled SIVmac239 replication as part of a recent experiment 
conducted by our laboratory (Table 1).32 As described above, a single infusion of the 
CD8β255R1 mAb resulted in near complete elimination of peripheral CD8αβ+ T-cells 
and a rise in NK cell counts in both r09089 and r09037, but especially in the former 
animal (Fig. 4A & B). Fluctuations in absolute counts of CD4+ T-cells and a modest 
increase in CD8αα+ T-cell numbers also ensued from the anti-CD8β mAb treatment (Fig. 
4 D & E). In contrast to r08019, but similar to the Group 1 macaques, both Group 3 
macaques experienced a surge in viremia after depletion of their CD8αβ+ T-cells (Fig. 
4F). Although r09037 transiently regained control of viral replication at wk 4 post 
treatment, SIV rebounded again shortly thereafter and VLs eventually leveled off at 100-
1,000 vRNA copies/mL (Fig. 4F). Monkey r09089 never reasserted full control of viral 
replication and its VLs ultimately plateaued in the same range as of r09037 (Fig. 4F). 
These results indicated that the lack of SIV rebound manifested by r08019 in the 
context of CD8αβ+ T-cell deficiency was not a general feature of controlled SIV 
infection.  
Next, we set out to explore whether CD8αα-expressing cells prevented SIV 
rebound in r08019 when its CD8αβ+ T-cells were eliminated. To address this possibility, 
we planned to treat r08019 and r04132 with the mouse/rhesus CDR-grafted anti-CD8α 
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mAb MT807R1 at wk 10 post CD8β depletion. We decided not to subject r07032 to this 
procedure since this animal had experienced adverse events during the CD8β255R1 
infusion. A potential risk of this experiment was the development of anaphylactic 
reactions triggered by anti-CD8β255R1 antibodies reacting against the MT807R1 Ig 
molecule. To estimate the levels of these cross-reactive anti-Ig responses, we coated 
ELISA plates with either CD8β255R1 or MT807R1 and screened pre- and post-CD8β 
depletion plasma for the presence of anti-Ig antibodies. The goal of this assay was to 
determine the highest plasma dilution where the OD value of the post-depletion sample 
was >2-fold higher than the corresponding pre-depletion sample (i.e. the endpoint titer). 
As expected, both r04132 and r08019 developed anti-CD8β255R1 antibodies after the 
CD8β depletion, with endpoint titers of 2,560 and 160, respectively (Fig. 5). However, 
we could not determine the endpoint titer of cross-reactive anti-MT807R1 antibodies in 
these monkeys since their pre- and post-CD8β depletion plasma samples yielded 
largely equivalent OD values, even at the lowest dilution (1:10) tested (Fig. 5). Since 
these data suggested that r08019 and r04132 had little or no anti-MT807R1 antibodies, 
we decided to proceed with the CD8α depletion.   
Even though we could not detect anti-MT807R1 antibodies in r08019, this animal 
experienced decreased oxygen saturation, abnormal heart rates, and vomiting during 
the MT807R1 infusion. Monkey r08019 recovered after receiving supportive care but 
ended up being treated with half of the planned dose of MT807R1. Conversely, r04132 
did not experience any adverse reactions and received the full dose of MT807R1. 
Although we administered only half of the desired amount of the anti-CD8α mAb to 
r08019, this dose was sufficient to transiently eliminate peripheral CD8α-expressing 
(CD8αα+ and CD8αβ+) T-lymphocytes and NK cells in this animal (Fig. 3B-D). Strikingly, 
SIV swiftly rebounded in r08019, peaking at 190,000 vRNA copies/mL on day 11 post 
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CD8α depletion (wk 38.4 PI; Fig. 3F). Macaque r04132 also experienced a brief rise in 
viremia that peaked at 9,900 vRNA copies/mL (Fig. 3F). Both animals regained control 
of viral replication in the ensuing weeks, concomitant with increases in absolute 
numbers of peripheral CD8αα+ T-cells and NK cells (Fig. 3C, D, & F). CD4+ T-
lymphocytes also expanded during this period, likely as a result of the CD8α depletion 
(Fig. 3E). These data suggested that effector lymphocytes expressing CD8αα 
homodimers, but not CD8αβ heterodimers, were responsible for maintaining virologic 
control in r08019.  
Infection with replication-impaired lentiviruses can also lead to controlled viremia, 
as evidenced by the detection of defective HIV-1 variants in long-term nonprogressor 
patients.56–61 To address this possibility, we set out to determine if the virus that infected 
r08019 harbored any unusual insertions, deletions, or mutations. We first searched for 
genetic variation in proviral sequences amplified from cryopreserved PBMC collected at 
wk 2 PI (Fig. 6A). All proviral sequences identified by this analysis contained two amino 
acid substitutions in Env (C432W and I863M; data not shown) and one in Nef (Y39C; Fig. 
6B). Additionally, an 18-bp in-frame deletion in nef corresponding to aa 139HRILDI144 
was present in 100% of the sequence reads (Fig. 6B & C). Interestingly, a similar 12-bp 
nef deletion affecting aa 143DIYL146 is found in the SIVmacC8 clone (Fig. 6B), which has 
been widely used as a live-attenuated SIV vaccine.62–66 The highly conserved core 
region of Nef altered by this deletion is functionally constrained, as evidenced by the 
instability and functionally impaired activity of the SIVmacC8 Nef protein.67 Moreover, 
SIVmac239 Nef lacking the same four amino acids that are absent from the SIVmacC8 
Nef protein also exhibits the same dysfunctional phenotype.67 Based on the similarity 
between the SIVmacC8 nef deletion and the deletion found in the virus discovered in 
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r08019, we concluded that this animal harbored an attenuated SIV variant as early as 
wk 2 PI. 
Curiously, the six amino acids affected by this deletion are contained within the 
Mamu-B*08-restricted Nef137-146RL10 epitope. In spite of this coincidence, r08019 tested 
negative for Mamu-B*08 in two independent MHC typing assays. Moreover, r08019 did 
not have detectable Nef-specific T-cell responses in an ICS assay performed at wk 3.4 
PI (Fig. 7), consistent with a mechanism for the emergence of the nef deletion that was 
independent from viral escape driven by T-cell pressure. 
To rule out the possibility that the nef deletion detected in r08019 was an 
experimental artifact, we sequenced the virus that rebounded following the CD8α 
depletion. Strikingly, 100% of circulating viral quasispecies contained the same deletion 
affecting aa 139HRILDI144 at wk 38.4 PI, the peak of rebound viremia (Fig. 6A & B). 
These viruses also exhibited signs of CD8+ T-cell-driven sequence evolution, as shown 
by escape mutations in the Mamu-A*01-restricted Tat28-35SL8 and Env726-735ST10 
epitopes (data not shown).68 However, the Gag181-189CM9 epitope was intact at this time 
point (data not shown). Of note, the Env (C432W and I863M) and Nef (Y39C) substitutions 
detected in cell-associated DNA at wk 2 PI were absent from plasma vRNA, indicating 
possible reversions (data not shown; Fig. 6B). These data confirmed our previous 
sequencing results and showed that the nef deletion was stably maintained in the 
course of r08019’s infection. 
Lastly, we investigated the origin of the nef deletion detected in r08019. Since 
this polymorphism was already present at wk 2 PI, we explored whether the challenge 
inoculum contained nef-deleted SIV variants that could have initiated infection in 
r08019. To do that, we performed whole genome sequencing on our SIVmac239 
challenge stock, which was produced by propagating the supernatant from transfected 
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293T cells on PBMC from SIV naïve rhesus macaques over several days. This analysis 
revealed a relatively homogeneous virus population, with low levels of viral diversity 
detected across the genome (Fig. 8). Importantly, there was no evidence of the nef 
deletion in the stock, although the aforementioned Env (C432W and I863M) and Nef 
(Y39C) amino acid substitutions were present at extremely low frequencies (<0.05%). Of 
note, the threshold frequency for detecting mutant species in this analysis was 0.05%, 
considering that each sequencing reaction contained approximately 2,000 copies of 
viral template. These results implied that either the nef deletion arose in vivo shortly 
after r08019 became infected or that a rare SIV variant bearing this polymorphism was 
present in the challenge inoculum, went undetected by our sequencing approach, and 
somehow managed to infect r08019.  
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DISCUSSION 
 
 Here we report the efficacy of a rDNA/rYF17D/rRRV PBB regimen encoding 
immunodominant SIV epitopes against repeated IR challenges with SIVmac239. Both 
Mamu-B*08+ Group 1 vaccinees controlled viral replication to levels rarely seen among 
MHC class I-matched historical control macaques that have been previously infected 
with SIVmac239. CD8αβ+ T-lymphocytes were likely responsible for this impressive 
outcome as mAb-mediated depletion of these cells resulted in transient increases in 
viremia. As for the Mamu-A*01+ Group 2 vaccinee r08019, virologic control appeared to 
involve CD8αα+ lymphocytes and an attenuating deletion in the nef gene, although it is 
also possible that SIV-specific CD8αβ+ T-cells participated in viral containment prior to 
the CD8β depletion. Although the mechanism underlying r08019’s impressive 
containment of SIV infection might not be generalizable, the uniqueness of this animal’s 
course of infection illustrates the complexity of lentivirus-host interactions. 
 The discovery of a nef-deleted SIV variant in r08019 remains a puzzling aspect 
of this study since this virus was found in all proviral sequences amplified at wk 2 PI but 
not in the challenge inoculum. Assuming that the low dose SIVmac239 IR challenge 
regimen employed here resulted in the transmission of a single virus, we can envision at 
least three possible explanations for the origin of this nef-deleted mutant. First, in spite 
of our inability to detect this deleted form in the SIVmac239 challenge stock, we cannot 
rigorously rule out the possibility that a minor variant harboring this change is what was 
transmitted. Indeed, deep sequencing of the inoculum revealed low levels of sequence 
diversity, probably as a result of propagating the virus on mitogen-activated rhesus 
macaque PBMC as part of its derivation method.69 Given the error-prone nature of 
retroviral reverse transcription, the low frequency SIV variants detected in the stock 
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likely represent byproducts of multiple rounds of viral replication in vitro. Furthermore, 
our inability to detect the nef-deleted virus in this stock would be in keeping with the 
technical problems inherent in searching for a rare polymorphism in a highly 
concentrated sample made almost exclusively of WT genomes.  
 Second, it is also possible that a reverse transcription error occurred in the first 
round of viral replication in vivo, resulting in the nef deletion in question. Indeed, short 
direct repeats are present near the ends of the 18-bp deletion in the SIVmac239 clone 
(Fig. 6C), similar to what has been observed in other examples of appearance of 
deletions in nef.70 These short direct repeats have been associated with the emergence 
of deletions in retroviral genomes by a mechanism involving template slippage during 
the reverse transcriptase reaction.71, 72 
A third possibility is that the nef deletion was selected for in vivo within the first 
two weeks after r08019 became infected. Although this 2-wk time frame might appear 
too short for the selection of the nef-deleted mutant, there is precedent for 
immunological pressures resulting in an altered variant virus with similar kinetics.32, 58, 73 
While the nature of the selection event(s) implicit in this model remains unknown, it 
probably did not involve T-cell responses since r08019 had no detectable Nef-specific 
T-cells in the acute phase (Fig. 7). Alternatively, the nef deletion might have emerged in 
response to selective pressure imposed by NK cells, potentially by a mechanism 
involving killer immunoglobulin-like receptor (KIR) recognition of viral epitopes 
presented by MHC class I molecules.74 Along these lines, specific aa substitutions in the 
HIV-1 proteome have been reported to be significantly enriched in infected individuals 
expressing combinations of KIR and MHC class I alleles, indicating that NK cells can 
drive HIV-1 escape.75, 76 Given the high epitope density of the core region of Nef,77 the 
deleted virus found in r08019 may have been selected for by KIR-expressing NK cells 
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targeting a peptide in that region. Much more extensive analysis will be required to 
investigate this last possibility. 
 The use of a new anti-CD8β mAb that selectively eliminates CD8αβ+ T-
lymphocytes in vivo without the caveat of depleting CD8αα-expressing rhesus macaque 
NK cells was a key part of this study. A single infusion of this antibody resulted in a 
surge of SIV replication in the Group 1 macaques but, surprisingly, not in r08019, 
indicating that this animal did not require an intact CD8αβ+ T-cell compartment to 
maintain control of chronic phase viremia. Importantly, the nef-deleted SIV variant that 
infected r08019 was clearly replication competent, as evidenced by the sharp rise in VL 
triggered by the subsequent CD8α depletion. These findings are intriguing and raise the 
question of what prevented this variant from rebounding in r08019 after the CD8β 
depletion. Of note, mAb-directed elimination of lymphocytes in tissues can be less 
efficient than what is observed in blood. Indeed, macaques subjected to the same 
CD8β255R1 infusion utilized here exhibited incomplete depletion of CD8+ T-cells in 
lymph node and duodenal biopsies in the first few weeks after the CD8β255R1 infusion 
(http://www.nhpreagents.org/NHP/Download.aspx?View=1&FileGUID=b7154cba-be30-
431c-834a-444c9376). In this regard, we cannot discard the possibility that residual 
SIV-specific CD8αβ+ T-cells present in relevant sites of SIV persistence prevented virus 
rebound in r08019 following the CD8β255R1 infusion. Alternatively, NK cells could also 
have suppressed viral replication during the period of CD8αβ+ T-cell deficiency. Along 
these lines, a vigorous expansion of NK cells coincided with the re-establishment of 
virologic control in the Group 1 macaques. Although epidemiological and in vitro data 
support a role for NK cells in lentivirus control,78 previous attempts to deplete these 
lymphocytes in vivo by the infusion of an anti-CD16 mAb revealed no significant 
contribution to the containment of SIV infection.79, 80 Critically, however, the majority of 
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rhesus macaque NK cells in the gut and vaginal mucosae do not express CD16,81 
indicating that in vivo depletion of CD16+ cells might not address the antiviral potential 
of tissue-resident NK cells. Considering this heterogeneity, it is difficult to assess the 
extent to which NK cells controlled viral replication in r08019 since our phenotypic 
analysis focused on CD3-CD8αα+CD16+ cells–the dominant NK cell subset in macaque 
peripheral blood.52 Thus, while our data provide circumstantial evidence for NK cell-
mediated control of SIV replication in one animal, they also illustrate the challenges of 
studying NK cells in nonhuman primates without more inclusive and selective strategies 
for depleting these lymphocytes in vivo.  
Given the increase in CD8αα+ T-cell counts after the CD8β depletion, especially 
in the Group 1 macaque r07032, we also considered the possibility that these cells 
contributed to control of SIV replication during this period. The physiological role of 
CD8αα homodimers expressed by T-cells is not completely understood. Previous 
studies in mice have shown that while both CD8αα and CD8αβ isoforms can bind to 
MHC class I molecules,82–84 CD8αβ heterodimers appear to be required for the 
selection of MHC class I-restricted CD8+ T-lymphocytes in the thymus.50 Furthermore, 
the CD8αα molecule has been described as a marker for T-cell activation and is 
primarily expressed by mucosal T-cells.51, 85, 86 Interestingly, human CD8αα+ T-cells 
residing in genital skin have been recently implicated in the containment of herpes 
simplex virus-2 reactivation,87 indicating that these cells participate in defense against 
persistent viral infections. Although CD8αα+ T-cells might be part of a unique, regionally 
specialized, lineage of T-lymphocytes, it is not clear if the peripheral CD8αα+ T-cells 
identified here are examples of such cells. Alternatively, they could have comprised pre-
existing CD8αα+CD8αβ+ T-cells in PBMC that internalized their surface CD8αβ 
heterodimers upon ligation of the anti-CD8β mAb. A detailed analysis of the T-cell 
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receptor clonotypes, Ag specificities, and tissue distribution of CD8αα+ and CD8αβ+ T-
cells before and after depletion of CD8αβ+ lymphocytes would have been needed to 
address this possibility. Nevertheless, in light of the recent identification of tissue-
resident human CD8αα+ T-cells endowed with potent antiviral activity,87 characterizing 
the role of these unconventional T-lymphocytes during lentivirus infections may lead to 
new strategies for eliciting cellular immunity against HIV. 
In conclusion, here we show that SIV-specific CD8+ T-cells elicited by a 
rDNA/rYF17D/rRRV PBB regimen afforded significant control of SIVmac239 replication 
in 3/4 vaccinees. Since vaccine-induced CD8+ T-cells in these animals were focused on 
a single immunodominant SIV epitope, we are currently exploring if expanding the CD8+ 
T-cell response against other viral Ags can improve vaccine efficacy. We also explored 
the basis for the unusual control of SIVmac239 replication manifested by one 
vaccinated macaque and showed that, surprisingly, this animal harbored a nef-deleted 
mutant as early as 2 wks PI. Subsequent CD8 depletions suggested that replication of 
this SIV variant may have been contained by CD8αα-expressing lymphocytes, 
warranting further investigation of the antiviral capacity of NK cells in vivo. While we 
could not pinpoint the origin of the nef-deleted virus, three possible explanations 
involving both stochastic and selective events were presented based on the available 
data. Collectively, these data provide additional insights into the full spectrum of 
virologic control of lentivirus infection.  
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FIGURE LEGENDS 
 
Figure 1. Design, immunogenicity, and efficacy of a rDNA/rYF17D/rRRV 
regimen encoding immunodominant classical CD8+ T-cell epitopes. A) Two 
Mamu-B*08+ (Group 1) and two Mamu-A*01+ (Group 2) Indian rhesus macaques 
were immunized with a heterologous prime/boost/boost vaccine regimen aimed 
at eliciting high frequency CD8+ TEM responses against immunodominant SIV 
determinants. These animals were primed once with rDNA delivered by 
intramuscular electroporation followed by two viral vector boosts with rYF17D 
and then rRRV. Both the rDNA plasmids and the rYF17D encoded SIVmac239 
minigenes corresponding to aa 45-210 of the Nef protein (Group 1) or aa 178-
258 of the Gag polyprotein (Group 2). The rRRV vectors expressed a rev-tat-nef 
fusion (Group 1) or full-length gag (Group 2). Of note, all macaques in Groups 1 
and 2 were seropositive for RRV at the time of the rRRV vaccinations. In keeping 
with the animals’ expressed MHC class I genotypes, macaques in Group 1 
received inserts encoding the Mamu-B*08-restricted Nef137-146RL10 epitope while 
those in Group 2 were vaccinated with gag sequences containing the Mamu-
A*01-restricted Gag181-189CM9 determinant. Nineteen weeks following the rRRV 
boost, we began challenging the Group 1 and Group 2 monkeys every week with 
intrarectal (IR) inoculations of 200 TCID50 of an in vivo-titered SIVmac239 
stock.32 B & C) Vaccine-induced SIV-specific CD8+ T-cell responses in Group 1 
(B) and Group 2 (C). We monitored the ontogeny of vaccine-elicited CD8+ T-cell 
responses in Groups 1 and 2 by staining PBMC with fluorochrome-labeled 
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Mamu-B*08/Nef137-146RL10 and Mamu-A*01/Gag181-189CM9 tetramers, 
respectively. Only time points following the rYF17D boost are displayed. The last 
measurement was performed at wk 34 post rYF17D vaccination, 3 wks prior to 
the 1st IR challenge with SIVmac239. D & E) Memory phenotype of vaccine-
induced CD8+ T-cells in Group 1 (D) and Group 2 (E) at wk 34 post rYF17D 
vaccination. Based on the expression of CD28 and CCR7, tetramer+CD8+ T-cells 
in PBMC were classified as fully-differentiated effector memory (TEM2; CD28–
CCR7–), transitional memory (TEM1; CD28+CCR7–), or central memory (TCM; 
CD28+CCR7+) subsets. F) Rate at which macaques in Groups 1 and 2 became 
infected following repeated IR challenges with SIVmac239. The frequency of 
each animal’s tetramer+CD8+ T-cells at wk 34 post rYF17D is shown as a 
reference. G) Log-transformed viral loads (VLs) after SIVmac239 infection. The 
dashed line in the graph is for reference only and indicates a VL of 106 vRNA 
copies/mL. The dotted line is also for reference only and denotes a VL of 103 
vRNA copies/mL. The limit of reliable quantitation of this VL assay was 15 vRNA 
copies/mL of plasma. To assess the extent to which vaccinees in Groups 1 and 2 
decreased plasma viremia, geometric means of VLs measured in unvaccinated 
MHC class I-matched macaques that were rectally infected with SIVmac239 as 
part of current and recent studies conducted in our laboratory are also plotted 
(Martins et al., unpublished observations).32, 33, 39 These geometric means were 
calculated based on VLs measured within wks 1-20 PI in twelve Mamu-B*08+ 
and eight Mamu-A*01+ macaques.   
 
Page 47 of 60
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
AIDS Research and Human Retroviruses
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only; Not for Distribution
Figure 2. Peak and setpoint viral loads in Groups 1 and 2 compared to 
historical SIVmac239-infected macaques. A) Log-transformed peak and 
setpoint VLs in r04132 and r07032 were plotted alongside the same VL values 
from Mamu-B*08+ rhesus macaques that were rectally infected with SIVmac239 
as part of ongoing and recent studies conducted in our laboratory (Martins et al., 
unpublished observations).32, 33, 39 Each symbol corresponds to one monkey. For 
this analysis, unvaccinated macaques (n = 12) are denoted by open circles 
whereas vaccinated monkeys (n = 16) are denoted by open triangles. B) Peak 
and setpoint VLs in r08019 and r01049 are displayed alongside VLs from 
SIVmac239-infected, Mamu-A*01+ rhesus macaques. As in A, open circles 
correspond to unvaccinated monkeys (n = 8) whereas open triangles indicate 
vaccinated animals (n = 8). In all cases, setpoint was determined as the 
geometric mean of VLs measured between wk 6 PI and the last available post-
infection time point. Bars correspond to medians. 
 
Figure 3. Outcome of sequential in vivo lymphocyte depletions. A) Both 
Group 1 vaccinees (r04132 and r07032) and r08019 received a single infusion of 
50 mg/kg of a new CD8β-specific mAb (CD8β255R1) designed to deplete CD8β-
expressing cells in vivo. At the time of the CD8β depletion, r04132 was at wk 31 
PI; r07032 was at wk 34 PI; and r08019 was at wk 27 PI. Ten weeks after the 
CD8β depletion, CD8α+ lymphocytes in r04132 and r08019 were depleted by a 
single infusion of 50 mg/kg of the anti-CD8α mAb MT807R1. Due to adverse 
events experienced during the CD8β depletion, r07032 was not subjected to this 
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treatment. B-E) Absolute lymphocyte counts in blood following the CD8β and 
CD8α depletions. B) CD8αβ+ T-cells (live CD3+CD8αα–CD8αβ+ lymphocytes). C) 
NK cells (live CD3–CD8αα+CD16+ lymphocytes). D) CD8αα+ T-cells (live 
CD3+CD8αα+CD8αβ– lymphocytes). E) CD4+ T-cells (considered as live 
CD3+CD8αα–CD8αβ– lymphocytes). F) Log-transformed VLs after the CD8β and 
CD8α depletions. The time points when r08019 experienced VLs at or above the 
limit of reliable quantitation (15 vRNA copies/mL) are crossed in red. VLs in this 
animal were <15 vRNA copies/mL at all other time points shown in panel F.  
 
Figure 4. Outcome of CD8β depletion in two additional SIV-infected 
macaques manifesting control of chronic phase viremia.  A) The Mamu-
B*08+ rhesus macaques r09089 and r09037 were rectally infected with 
SIVmac239 as part of a recent experiment conducted by our laboratory and 
controlled chronic phase viremia32. Similar to the procedure described in Fig. 3, 
these animals received a single infusion of 50 mg/kg of the CD8β255R1 mAb. At 
the time of the CD8β depletion, r09089 was at wk 103 PI and r09037 was at wk 
109 PI. B-E) Absolute lymphocyte counts in blood following the CD8β and CD8α 
depletions. B) CD8αβ+ T-cells (live CD3+CD8αα–CD8αβ+ lymphocytes). C) NK 
cells (live CD3–CD8αα+CD16+ lymphocytes). D) CD8αα+ T-cells (live 
CD3+CD8αα+CD8αβ– lymphocytes). E) CD4+ T-cells (considered as live 
CD3+CD8αα–CD8αβ– lymphocytes). F) Log-transformed VLs after the CD8β 
depletion.  
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Figure 5. Endpoint titers of anti-Ig antibodies in r04132 and r08019. Pre- and 
post-CD8β depletion plasma from r04132 (A) and r08019 (B) were tested for 
reactivity to the CD8β255R1 (left panels) and MT807R1 (right panels) mAbs. The 
goal of this assay was to determine the endpoint titer of antibodies against each 
mAb, that is, the highest plasma dilution where the absorbance level of the post-
depletion sample was >2-fold higher than the corresponding pre-depletion 
sample. Plasma saved 8 days before and 22 days after the CD8β255R1 infusion 
served as the pre- and post-depletion samples, respectively. The endpoint titers 
of anti-CD8β255R1 antibodies are underlined and in boldface type below each 
graph. Anti-MT807R1 antibodies could not be detected in either r04132 or 
r08019 by this methodology.  
 
Figure 6. Viral sequencing analysis in r08019. A) Scheme of the viral 
sequencing analysis performed in r08019. We searched for genetic variation in 
SIV DNA obtained from cryopreserved PBMC collected at wk 2 PI. Viral 
sequences from nucleotides 7,565-9,979 were amplified, which encode aa 324-
879 of Env and the entire Nef protein (aa 1-263). Eleven days after the infusion 
of the anti-CD8α mAb, when r08019 experienced a VL of 190,000 vRNA 
copies/mL (wk 38.4 PI), we isolated vRNA from plasma and sequenced the SIV 
genomes circulating at this time point. B) Alignment of predicted Nef amino acid 
sequences found in r08019. Conceptual translations of the nef sequences 
obtained from PBMC-associated SIV DNA at wk 2 PI and from plasma vRNA at 
wk 38.4 PI are shown in the upper rows. As a reference, the aa sequence of the 
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SIVmac239 Nef protein is shown in the bottom row. The location of the six-amino 
acid Nef deletion (139HRILDI144) found in r08019 is indicated by a box. The Y39C 
substitution present in SIV DNA at wk 2 PI is also enclosed by a box. However, 
this mutation was not detected in the rebounding virus following the CD8α 
depletion. The sequence corresponding to the SIVmacC8 nef deletion is 
underlined. C) Short direct nucleotide repeats near the limits of the deleted 
region in nef are underlined. These repeated stretches are 8 nucleotides long, 
seven of which are identical in each repeat. The position of the nucleotides 
relative to the SIVmac239 genome is indicated on top and the deleted aa region 
is enclosed by a box. The nef deletion overlaps with the 3’ long terminal repeat 
U3 region, which spans nucleotides 9,452-9,978.  
 
Figure 7. Post-infection analysis of SIV-specific T-cell responses in r08019. 
We carried out an intracellular cytokine staining assay in PBMC from r08019 at 
wk 3.4 PI. The stimuli consisted of pools of peptides spanning the entire Nef 
protein or three segments of the Gag polyprotein. A peptide corresponding to the 
Mamu-A*01-restricted Gag181-189CM9 epitope was included as well. Reactivity to 
each stimulus is shown based on the production of IFN-γ and/or TNF-α. CD8+ 
and CD4+ T-lymphocytes are shown in the top and bottom rows, respectively.  
 
Figure 8. Genome-wide deep sequencing of the SIVmac239 stock used for 
the IR challenges. Heat map illustration of the level of sequence variation 
across the SIVmac239 genome detected from 454 deep sequencing. Plotted is 
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the percentage of amino acid diversity at each position across the genome with 
the first amino acid of Gag located in the top left corner of the grid and the last 
amino acid of Nef located in the bottom right corner. Completely conserved 
codons are black and low-level variant residues (<10%) are colored light blue.   
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TABLE 1. Animal characteristics. 
Exptl group Animal ID MHC-I alleles Age (yrs)1 Gender 
Group 1 r04132 Mamu-B*08 8.3 Female 
 r07032 Mamu-B*08 5.3 Male 
     
Group 2 r08019 Mamu-A*01 4.7 Female 
 r01049 Mamu-A*01 11.7 Male 
  
Group 3 r09037 Mamu-B*08 6.2 Female 
 r09089 Mamu-B*08 5.8 Male 
  
 
1 Animal age at beginning of study. 
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